Ibipinabant

Ibipinabant (pronounced as i-bi-pin-a-bant) is a drug that was developed by Sanofi-Aventis for the treatment of obesity. It acts as a selective CB1 antagonist.

Etymology

The term "Ibipinabant" is derived from the IUPAC name for the compound, which is (R)-3-(2,4-dichlorophenyl)-4-[(4-((1-piperidinyl)methyl)phenyl)methyl]-1-piperidinyl]-1H-pyrazole. The name "Ibipinabant" is a portmanteau of parts of this IUPAC name.

Pharmacology

Ibipinabant works by blocking the cannabinoid receptor CB1, which is found primarily in the brain and is involved in the regulation of appetite. By blocking this receptor, Ibipinabant reduces the desire to eat and can help to control weight.

Clinical Trials

Ibipinabant was tested in clinical trials for the treatment of obesity, but development was discontinued in 2008 due to concerns about side effects, including depression and anxiety.

Related Terms

• Cannabinoid receptor antagonist
• CB1
• Sanofi-Aventis
• Obesity

See Also

• List of drugs for obesity
• List of discontinued drugs

External links

• Medical encyclopedia article on Ibipinabant
• Wikipedia's article - Ibipinabant

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski